Empowering patients for biomarker-informed care: digital education to bridge HER2-low knowledge gaps in metastatic breast cancer

The emergence of trastuzumab deruxtecan has led to significant improvement in clinical outcomes for patients with HER2-low metastatic breast cancer, which accounts for approximately half (45%–55%) of breast cancer diagnoses. However, little is known about patients’ awareness of diagnostic testing requirements and treatment implications associated with HER2-low status. This study aims to better understand patients’ knowledge of HER2-low.